FDA expands Mounjaro approval for cardiovascular risk reduction in type 2 diabetes

The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce heart attack and stroke risk in high-risk adults with type 2 diabetes. This decision, based on a trial showing an 8% lower rate of cardiovascular events compared to Trulicity, is expected to boost sales and improve insurance coverage for the drug. This provides a new therapeutic option for managing cardiovascular complications in diabetic patients.